Fasting Study of Metolazone Tablets 5 mg and Zaroloxyn® Tablets 5 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Zaroloxyn® Tablets 5 mg
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 52
- Registration Number
- NCT00649181
- Locations
- 🇺🇸
Kendle International Inc., Morgantown, West Virginia, United States
Fed Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 36
- Registration Number
- NCT00648219
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Comparative Bioavailability Study of Clarithromycin 500 mg Tablets in Fasting State
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 64
- Registration Number
- NCT00648960
- Locations
- 🇨🇦
Algorithme Pharma, Laval, Quebec, Canada
Evaluation of Adhesion Quality of a New Formulation of the Mylan Estradiol Transdermal System 0.025 mg/Day and Climara® Transdermal System 0.025 mg/Day
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Mylan Estradiol Transdermal System 0.025 mg/day
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 76
- Registration Number
- NCT00649896
- Locations
- 🇺🇸
SFBC International, Miami, Florida, United States
Fasting Study of Albuterol Sulfate Extended-Release Tablets 8 mg and VoSpire® ER Tablets 8 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: VoSpire™ ER 8 mg tablets
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 21
- Registration Number
- NCT00649779
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Evaluation of Adhesion Quality and Irritation of an Alternate Second Generation Estradiol Transdermal System
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 39
- Registration Number
- NCT00650442
- Locations
- 🇺🇸
Kendle International Inc., Morgantown, West Virginia, United States
Comparative Bioavailability Study of Clarithromycin 500 mg Tablets in Fed State
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 44
- Registration Number
- NCT00648128
- Locations
- 🇨🇦
Algorithme Pharma, Laval, Quebec, Canada
Fasting Study of Terbinafine Hydrochloride Tablets 250 mg and Lamisil® Tablets 250 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 36
- Registration Number
- NCT00647647
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Food Study Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR 500 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 18
- Registration Number
- NCT00648492
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Fasting Study of Glimepiride Tablets 1 mg to Amaryl® Tablets 1 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 40
- Registration Number
- NCT00648362
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
© Copyright 2025. All Rights Reserved by MedPath